Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD036 dose-ranging 30-day trial in obstructive sleep apnoea
ACTRN12619001153101Phase 2Completed
- Sponsor
- Flinders University
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine + oxybutynin in obstructive sleep apnea hypopnea syndrome (OSAHS) (4 arms), sponsored by Flinders University. Primary endpoints: Change in apnoea/hypopnoea index, Adverse events and tolerability and 1 more. Started Oct 2019; status: completed.
02
Drugs
atomoxetine + oxybutynin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12619001153101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001153101.